Long-term fasting improves lipoprotein-associated atherogenic risk in humans.

Purpose: Dyslipidemia is a major health concern associated with an increased risk of cardiovascular mortality. Long-term fasting (LF) has been shown to improve plasma lipid profile. We performed an in-depth investigation of lipoprotein composition. Methods: This observational study included 40 volun...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nutrition Vol. 60; no. 7; pp. 4031 - 4045
Autores principales: Grundler, Franziska, Plonné, Dietmar, Mesnage, Robin, Müller, Diethard, Sirtori, Cesare R., Ruscica, Massimiliano, Wilhelmi de Toledo, Françoise
Formato: clinical trial research tables/charts Journal Article
Publicado: Springer Nature Oct2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=152423265&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 152423265
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14366207
        CR0
      jtl: European Journal of Nutrition
      issn: 14366207
      maglogo: N
    pubinfo:
      dt: Oct2021
      vid: 60
      iid: 7
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        152423265
        150193412
        152423265
        152423265
        10.1007/s00394-021-02578-0
        152423265
      ppf: 4031
      ppct: 14
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Long-term fasting improves lipoprotein-associated atherogenic risk in humans.
      aug:
        au:
          Grundler, Franziska
          Plonné, Dietmar
          Mesnage, Robin
          Müller, Diethard
          Sirtori, Cesare R.
          Ruscica, Massimiliano
          Wilhelmi de Toledo, Françoise
        affil: Buchinger Wilhelmi Clinic, Wilhelm-Beck-Straße 27, 88662, Überlingen, Germany
      sug:
        subj:
          Fasting
          Time Factors
          Lipoproteins Blood
          Atherosclerosis Prevention and Control
          Treatment Outcomes
          Human
          Nonexperimental Studies
          Male
          Female
          Adult
          Middle Age
          Aged
          Centrifugation
          Magnetic Resonance Imaging
          Triglycerides
          Lipoproteins, LDL
          Magnetic Resonance Spectroscopy
          Lipoproteins, HDL
          Apolipoproteins
          Fibrinogen
          C-Reactive Protein
          Clinical Trials
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Purpose: Dyslipidemia is a major health concern associated with an increased risk of cardiovascular mortality. Long-term fasting (LF) has been shown to improve plasma lipid profile. We performed an in-depth investigation of lipoprotein composition. Methods: This observational study included 40 volunteers (50% men, aged 32–65 years), who underwent a medically supervised fast of 14 days (250 kcal/day). Changes in lipid and lipoprotein levels, as well as in lipoprotein subclasses and particles, were measured by ultracentrifugation and nuclear magnetic resonance (NMR) at baseline, and after 7 and 14 fasting days. Results: The largest changes were found after 14 fasting days. There were significant reductions in triglycerides (TG, − 0.35 ± 0.1 mmol/L), very low-density lipoprotein (VLDL)-TG (− 0.46 ± 0.08 mmol/L), VLDL-cholesterol (VLDL-C, − 0.16 ± 0.03 mmol/L) and low-density lipoprotein (LDL)-C (− 0.72 ± 0.14 mmol/L). Analysis of LDL subclasses showed a significant decrease in LDL1-C (− 0.16 ± 0.05 mmol/L), LDL2-C (− 0.30 ± 0.06 mmol/L) and LDL3-C (− 0.27 ± 0.05 mmol/L). NMR spectroscopy showed a significant reduction in large VLDL particles (− 5.18 ± 1.26 nmol/L), as well as large (− 244.13 ± 39.45 nmol/L) and small LDL particles (− 38.45 ± 44.04 nmol/L). A significant decrease in high-density lipoprotein (HDL)-C (− 0.16 ± 0.04 mmol/L) was observed. By contrast, the concentration in large HDL particles was significantly raised. Apolipoprotein A1 decreased significantly whereas apolipoprotein B, lipoprotein(a), fibrinogen and high-sensitivity C-reactive protein were unchanged. Conclusion: Our results suggest that LF improves lipoprotein levels and lipoprotein subclasses and ameliorates the lipoprotein-associated atherogenic risk profile, suggesting a reduction in the cardiovascular risk linked to dyslipidemia. Trial Registration: Study registration number: DRKS-ID: DRKS00010111 Date of registration: 03/06/2016 "retrospectively registered".
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N